GEN Exclusives

More »

GEN News Highlights

More »
Jan 30, 2007

Amylin and PsychoGenics Create Psychiatric-Focused Company

  • PsychoGenics collaborated with Amylin Pharmaceuticals to form Psylin Neurosciences, a new company that will focus on the discovery and development of peptide hormones for the treatment of psychiatric disorders.

    “The creation of Psylin affords both companies the opportunity to pursue a new area of research, while maintaining their corporate focus," says Emer Leahy, Ph.D., president and CEO of PsychoGenics.

    Both companies participated equally in a Series A financing of Psylin that is anticipated to fund the company for the next two years.

    Under this new venture, Psylin will have access to molecules in Amylin's polypeptide hormone library, Phormol™, and to PsychoGenics' drug discovery technologies. Psylin will also have the right to develop a number of drug candidates emerging from this collaboration.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Tackling Climate Change

Do you think most companies will respond positively to the People’s Climate March?